

Preoperative Chlorhexidine Gluconate Bathing Could Prevent Post-obstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial

08/08/2025 07:24:14

_				4 8		
IN.	n	•	~~	41	\sim	-
ı.						

Primary registry identifying number

LBCTR2019121361

MOH registration number

Study registered at the country of origin

Type of registration

Prospective

Date of registration in national regulatory

20/12/2019

Primary sponsor

Beirut Arab University

Date of registration in primary registry

24/12/2019

Public title

Preoperative Chlorhexidine Gluconate Bathing Could Prevent Postobstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial

Scientific title

Preoperative Chlorhexidine Gluconate Bathing Could Prevent Postobstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial

Brief summary of the study: English

Protocol number

HD2305

Study registered at the country of origin: Specify

Type of registration: Justify

N/A

Primary sponsor: Country of origin

Date of registration in national regulatory agency

20/12/2019

Acronym

Acronym





Background: Bathing with chlorhexidine gluconate is a novel practice that reduces the microbial burden on skin. There is limited data on chlorhexidine gluconate bathing in obstetric and gynecological surgeries in Lebanon.

Objective: To test the feasibility of a randomized controlled trial through a pilot design to evaluate the effect of preoperative chlorhexidine gluconate bathing on reducing surgical-site infections in obstetric and gynecological surgeries involving abdominal incisions.

Methods: Participants will be randomized into the intervention or usual care group. Participants in the intervention group will bath with 4% chlorhexidine gluconate sponge on the day of the surgery. They will apply the product between the upper two-thirds of the thighs and abdomen just below the breasts for 5 minutes. The rest of the body will be bathed normally as usual care. The bathing will be consistent by all participants. While participants in the usual care group will be left to practice what the healthcare facility usually advises them to do. Outcomes will be collected at day 10 and 30 after the surgery for surgical site infections defined by the presence of pus in the wound in addition to possible redness, warmth, discharge or dehisces in the wound or infectious morbidity such as fever or abdominal pain.

Brief summary of the study: Arabic

هذه الدراسة تختبر تأثير استخدام كلور هيكسيدين جلوكونيت في التعقيم قبل اجراء العمليات الجراحية التوليدية والمتعلقة بأمراض النساء على .
خفض احتمال حدوث الالتهابات في منطقة الجرح .
سينقسم المشتركون في الدراسة عشوانيا الى مجمو عتين، حيث ستستخدم مجوعة منهم الكلور هيكسيدين في تعقيم المنطقة ما بين البطن وحتى ثاثي .
الفخدين، والأخرى ستستخدم الأساليب التقليدية في التعقيم لدى المستشفى .
يوم من تاريخ إجراء العملية لوجود اي مؤشر للالتهابات30 و 10أما النتائج، فستجمع بعد

Health conditions/problem studied: Specify

Infection post-surgery on the surgical site

Interventions: Specify

A daily visit to the named hospitals will be done by Researcher I to check the following day's operating room schedule for any planned OBS/GYN abdominal surgeries. Participants with planned surgeries will be approached upon admission and introduced to the study. Each participant will be allocated to a study code. Participants will sign the consent form and complete the baseline questionnaire. They will then be randomized based on their study code. Participants allocated to the intervention group will be instructed by Researcher I on the use of CHG before leaving to the surgery. CHG will be provided to the participants to perform the bath. Participants will be instructed to emphasize the CHG application between the upper two-thirds of the thighs and abdomen just below the breasts for 5 minutes. The rest of the body will be bathed normally as usual care. Same instructions will be given to all participants in the intervention group by the same researcher to assure consistency. Tools and figures will be used to enhance explanation. Adherence to intervention will be assured when giving the antiseptic and asking to bath immediately.

Key inclusion and exclusion criteria: Inclusion criteria

Adult women presenting to the hospitals OBS/GYN pre-surgery wards during the study period; they will be included if they were presented for a planned surgery, consenting to participate and will be available for follow up, regardless of their nationality.

45

N/A

N/A

Key inclusion and exclusion criteria: Gender

Key inclusion and exclusion criteria: Specify gender

Female

Key inclusion and exclusion criteria: Age minimum

Key inclusion and exclusion criteria: Age maximum

18

Key inclusion and exclusion criteria: Exclusion criteria

Participants will be excluded if they have known allergy to chlorhexidine or have a condition impeding them from participation such as blindness, deafness or cognitive impairment.

Type of study

Interventional

Type of intervention Type of intervention: Specify type

Educations programs

Trial scope Trial scope: Specify scope

Prophylaxis



Study design: Allocation Randomized controlled trial

Study design: Control

Placebo

Study design: Purpose

Prevention

Study design: Assignment

Parallel

IMP has market authorization

Study design: Masking

Open (masking not used)

Study phase

0 (explanatory trials)

Study design: Specify purpose

N/A

Study design: Specify assignment

IMP has market authorization: Specify

Year of authorization Month of authorization

Type of IMP

Name of IMP

Pharmaceutical class

Chlorhexidine is a broad-spectrum antiseptic effective against Gram-positive and negative bacteria (WHO, 2008).

Therapeutic indication

CHG reduces microbial colonization on the skin, and thus, is used in many of the hospitals to reduce the risk of having health-care associated infections.

Therapeutic benefit

Chlorhexidine is used for disinfection instead of Betadine in many of the hospitals, but its effect has not yet been established in reducing the risk of infection; therefore, this trial is being conducted to evaluate its effect on reducing the risk of post-operative infections in the site of the surgical wound.

Study model Study model: Explain model

N/A

Study model: Specify model

N/A

Time perspective Time perspective: Explain time perspective

N/A N/A

Time perspective: Specify perspective

Target follow-up duration Target follow-up duration: Unit

Number of groups/cohorts

Biospecimen retention Biospecimen description

None retained





WBC will be assessed after 10 days from surgery to detect any presence of infections.

Target sample size

Date of first enrollment: Type

Anticipated

Date of study closure: Type

Anticipated

Recruitment status

Pending

Date of completion

29/05/2020

IPD sharing statement plan

No

Additional data URL

Admin comments

Trial status

Approved

Actual enrollment target size

Date of first enrollment: Date

03/02/2020

Date of study closure: Date

29/05/2020

Recruitment status: Specify

IPD sharing statement description

Data will be shared if the reviewers find it necessary to maintain confidentiality and avoid the risk of breathing confidential data that may be identifiable due to the small sample size and the small community.

Secondary Identifying Numbers Full name of issuing authority Secondary identifying number 01300110 Beirut Arab University

Sources of Monetary or Material Support Name Dr. Hiba Deek Ms. Nour Shbaklo



Secondary Sponsors	
Name	
none	

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Hiba Deek	Beirut	Lebanon	01300110	h.deek@bau.edu .lb	BAU
Scientific	Hiba Deek	Beirut	Lebanon	01300110	h.deek@bau.edu .lb	BAU

Centers/Hospitals Involved in the Study				
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval	
Rafic Hariri University Hospital	Ms. Nour Shbaklo	Infection Prevention and Control	Approved	
Makassed General Hospital	Ms. Nour Shbaklo	Infection Prevention and Control	Approved	

Ethics Review	thics Review						
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone			
Rafic Hariri University Hospital	26/12/2018	Mrs. Abir Sinno	abir.sinno@crurhuh.com	00000000			
Makassed General Hospital	18/12/2018	Ms. Loubna	research.makassed@hotmail.com	00000000			

Countries of Recruitment		
Name		
Lebanon		

Health Conditions or Problems Studied		
Condition	Code	Keyword
infection	Infection of obstetric surgical wound (O86.0)	infection



Interventions			
Intervention	Description	Keyword	
Use of CHG in bathing prior to surgery	Bathing with CHG from abdomen until two- thirds of the thighs	CHG	

Primary Outcomes		
Name	Time Points	Measure
Infection	10 and 30 days	inspection and blood tests

Key Secondary Outcomes			
Name	Time Points	Measure	
none	none	none	



Trial Results			
Summary results			
Study results globally			
Date of posting of results summaries	Date of first journal publication of results		
Results URL link			
Baseline characteristics			
Participant flow			
Adverse events			
Outcome measures			
URL to protocol files			